Sugi Predict

Sugi Predict / Targets / DCAF1

DCAF1

DDB1- and CUL4-associated factor 1 · Q9Y4B6 · DCAF1 on Sugi Atlas →

1,165 patent compounds predicted against DCAF1, 474 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL27369861 SCHEMBL27369861 0.65 16/20
SCHEMBL26470124 SCHEMBL26470124 0.59 16/20
SCHEMBL27369844 SCHEMBL27369844 0.59 16/20
SCHEMBL27278326 SCHEMBL27278326 0.58 16/20
SCHEMBL27278325 SCHEMBL27278325 0.56 16/20
SCHEMBL27369836 SCHEMBL27369836 0.53 16/20
SCHEMBL27369820 SCHEMBL27369820 0.63 15/20
SCHEMBL27369904 SCHEMBL27369904 0.51 15/20
SCHEMBL26795044 SCHEMBL26795044 0.65 14/20
SCHEMBL27278324 SCHEMBL27278324 0.63 14/20
SCHEMBL26795041 SCHEMBL26795041 0.66 13/20
SCHEMBL22896308 SCHEMBL22896308 0.64 11/20
SCHEMBL27849839 SCHEMBL27849839 0.56 11/20
SCHEMBL22897124 SCHEMBL22897124 0.53 11/20
SCHEMBL10184458 SCHEMBL10184458 0.41 11/20
SCHEMBL22896186 SCHEMBL22896186 0.58 10/20
SCHEMBL6168207 SCHEMBL6168207 0.53 10/20
SCHEMBL17375914 SCHEMBL17375914 0.53 10/20
SCHEMBL22896743 SCHEMBL22896743 0.53 10/20
SCHEMBL22897198 SCHEMBL22897198 0.53 10/20

Clinical trials — most relevant to DCAF1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy PHASE1/PHASE2RECRUITING
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study nanRECRUITING
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures. nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer nanCOMPLETED
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer nanACTIVE_NOT_RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
ADAPT: Efficacy of a Dietary Supplement During and After Exercise nanCOMPLETED
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Better Delineation of DDX3X Related Phenotype and Epigenetic Signature. nanUNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Mitochondrial Function of Immune Cells in Sepsis nanCOMPLETED
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a DCAF1 binder may also engage these)

ProteinNameSimilarity
Q80TR8 — 1.000 Q80TR8 →
Q9ESE1 — 0.992 Q9ESE1 →
B1AY13 — 0.991 B1AY13 →
Q9EPN1 — 0.990 Q9EPN1 →
Q8IV36 — 0.990 Q8IV36 →
USP24 Ubiquitin carboxyl-terminal hydrolase 24 0.990 landscape →
Q28653 — 0.990 Q28653 →
O94915 — 0.990 O94915 →
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform 0.990 landscape →
Q9Y3R5 — 0.990 Q9Y3R5 →
Q9ULT8 — 0.989 Q9ULT8 →
LRBA Lipopolysaccharide-responsive and beige-like anchor protein 0.989 landscape →
Q9CQ73 — 0.988 Q9CQ73 →
Q9W4E2 — 0.988 Q9W4E2 →
Q7Z3E5 — 0.987 Q7Z3E5 →
Q3UHQ6 — 0.987 Q3UHQ6 →
Q14D04 — 0.987 Q14D04 →
A2VE70 — 0.987 A2VE70 →
Q5PQS3 — 0.987 Q5PQS3 →
Q5TBA9 — 0.987 Q5TBA9 →
Q68F38 — 0.987 Q68F38 →
Q69ZR2 — 0.986 Q69ZR2 →
Q96N67 — 0.986 Q96N67 →
Q8NFP9 — 0.986 Q8NFP9 →
Q5T2E6 — 0.986 Q5T2E6 →
Q6P1Y8 — 0.986 Q6P1Y8 →
Q2KI89 — 0.986 Q2KI89 →
Q6ZS30 — 0.986 Q6ZS30 →
Q9W2F2 — 0.986 Q9W2F2 →
Q5JWR5 — 0.986 Q5JWR5 →